Guggenheim initiated coverage of DBV Technologies (DBVT) with a Buy rating and $35 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
- DBV Technologies announces last patient visit completed in VITESSE trial
- DBV Technologies appoints Kevin Trapp as chief commercial officer
- DBV Technologies Appoints Dr. Philina Lee to Board
- DBV Technologies price target raised to $20 from $16 at H.C. Wainwright